Sung Yoon Baek

USPTO Granted Patents = 9 (Patent Applications = 1)

CIPO Patents = 3 (Patent Applications = 2)

EPO Patents = 3 (Patent Applications = 6)

Average Co-Inventor Count = 10.3

ph-index = 2

Forward Citations = 7(Granted Patents)

Company Filing History:

6 out of 25

Legochem Biosciences, Inc.

patents

3 out of 4

Legochem Bioscience Ltd.

patents

1 out of 260

The Green Cross Corporation

patents

where one patent can have more than one assignee

Years Active: 2012-2019

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 10273235 - Compositions and methods for inhibiting β-lactamase (2019-04-30),

2. 9988372 - Crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate and pharmaceutical composition comprising same (2018-06-05),

3. 9951072 - Compositions and methods for inhibiting beta-lactamase (2018-04-24),

4. 8846669 - Oxazolidinone derivative and medical composition containing same (2014-09-30),

5. 8703939 - Method for preparing (R)-3-(3-fluoro-4-(1-methyl-5,6-dihydro-1,2,4-triazin-4(1H)-yl)phenyl)-5-(substituted methyl)oxazolidin-2-one derivatives (2014-04-22),

6. 8637667 - Method for preparing (S)-5-chloro-N-((3-(4-(5,6-dihydro-4H-1,2,4-oxadiazin-3-yl)phenyl)-2-oxooxazolidin-5-yl)methyl)thiophene-2-carboxamide derivatives (2014-01-28),

7. 8288423 - FXa inhibitors with cyclic amidines as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof (2012-10-16),

8. 8242113 - Oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone pharmaceutical compositions thereof (2012-08-14),

9. 8178525 - FXA inhibitors with cyclic amidoxime or cyclic amidrazone as P4 subunit, processes for their preparations, and pharmaceutical compositions and derivatives thereof (2012-05-15),

Title: Innovations and Contributions of Inventor Sung Yoon Baek

Introduction

Sung Yoon Baek is a prominent inventor based in Daejeon, South Korea. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that inhibit β-lactamase. With a total of 9 patents to his name, Baek's work has the potential to impact medical treatments significantly.

Latest Patents

Baek's latest patents include compositions and methods for inhibiting β-lactamase. He has developed substituted dihydroisoxazole derivatives that serve as effective inhibitors of β-lactamases, which are crucial in combating antibiotic resistance. Another notable patent involves a novel crystalline form of 5-chloro-N-({(5S)-2-oxo-3-[4-(5,6-dihydro-4H-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophene-2-carboxamide methanesulfonate. This invention demonstrates excellent stability in high-temperature and humidity environments, making it suitable for preventing or treating various diseases, including thrombosis and myocardial infarction.

Career Highlights

Throughout his career, Baek has worked with notable companies such as Legochem Biosciences, Inc. and Legochem Bioscience Ltd. His expertise in pharmaceutical sciences has allowed him to contribute to innovative solutions in the medical field.

Collaborations

Baek has collaborated with esteemed colleagues, including Young Lag Cho and Yong Zu Kim. These partnerships have fostered a collaborative environment that enhances the development of groundbreaking inventions.

Conclusion

Sung Yoon Baek's contributions to the field of pharmaceuticals through his innovative patents and collaborations highlight his role as a significant inventor. His work continues to pave the way for advancements in medical treatments and drug development.

This text is generated by artificial intelligence and may not be accurate.